Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ECE1 | P42892 | 4/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | FAAH | O00519 | 2/20 | 0.40 |
| ▸ | CNR1 | P21554 | 2/20 | 0.40 |
| ▸ | CNR2 | P34972 | 2/20 | 0.40 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9201859 | 0.88 | TP53 (0.56) | ECE1TP53SMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL9831393 | 0.86 | KMT2A (0.57) | TP53SMN1; SMN2ALDH1A1HPGDKMT2A | |
| SCHEMBL24711404 | 0.84 | ADRA1A (0.58) | TP53SMN1; SMN2ALDH1A1HPGDKMT2A | |
| SCHEMBL24711402 | 0.84 | ADRA1A (0.58) | TP53SMN1; SMN2ALDH1A1HPGDKMT2A | |
| SCHEMBL24711393 | 0.84 | ADRA1A (0.58) | TP53SMN1; SMN2ALDH1A1HPGDKMT2A | |
| SCHEMBL23281610 | 0.84 | ADRA1A (0.58) | TP53SMN1; SMN2ALDH1A1HPGDKMT2A | |
| SCHEMBL9829747 | 0.84 | ADRA1A (0.58) | TP53SMN1; SMN2ALDH1A1HPGDKMT2A | |
| SCHEMBL18908668 | 0.84 | SMN1; SMN2 (0.59) | TP53SMN1; SMN2ALDH1A1HPGDKMT2A | |
| SCHEMBL15071678 | 0.83 | SMN1; SMN2 (0.50) | ECE1TP53SMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL25602361 | 0.83 | SMN1; SMN2 (0.50) | ECE1TP53SMN1; SMN2ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11873291-B2 | Quinoline cGAS antagonist compounds | IMMUNESENSOR THERAPEUTICS, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| US-20230357158-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2023-11-09 | — | — | US | disclosed |
| US-20220395589-A1 | POLYMERIC NANOPARTICLES FOR INTRACELLULAR PROTEIN DELIVERY | THE JOHNS HOPKINS UNIVERSTY | 2022-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11873291-B2 | Quinoline cGAS antagonist compounds | CGAS, GLS2, GLS | ECE1 1039/4885TP53 503/4885SMN1; SMN2 2633/4885 |
| US-20230357158-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | CGAS, GLS2, GLS | ECE1 1039/4885TP53 503/4885SMN1; SMN2 2633/4885 |
| US-20220395589-A1 | POLYMERIC NANOPARTICLES FOR INTRACELLULAR PROTEIN DELIVERY | LNPEP, EEA1, CLTB | ECE1 1427/4885TP53 1301/4885SMN1; SMN2 2984/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.